Key result
The purinergic signalling system, including extracellular ATP and P2 receptors, amplifies inflammation in vivo and represents a novel therapeutic target for inflammatory diseases.
The purinergic signaling system, involving extracellular ATP and P2 receptors, plays a key role in modulating inflammation and presents novel therapeutic opportunities for inflammatory diseases.
May inform novel anti-inflammatory drug development; leaves open clinical efficacy pending targeted trials.
Inflammation is an important homeostatic response, which is managed by a complex network of interrelated pathways that determine the level, intensity and localization of inflammation. We now know that purinergic signalling is one of the pathways influencing the initiation, progression and down-modulation of the inflammatory response. Here, we review recent evidence on the role in inflammation of the purinergic signalling system, which is comprised of extracellular ATP, P2 receptors and ecto-enzyme cascades. Recent animal studies with a newly developed bioluminescent ATP probe (pmeLUC), enabling measurement of pericellular ATP in situ, have provided proof that ATP is present in inflamed tissues in vivo at extracellular concentrations sufficient for P2 receptor activation. Increased extracellular ATP levels amplify inflammation in vivo by promoting leukocyte recruitment and NALP3-inflammasome activation via P2X7. Lowering extracellular ATP levels in inflamed tissues, for instance by stimulating its breakdown, inhibits the inflammatory response in vivo. In view of its important role in inflammation, the purinergic signalling system is bound to yield novel therapeutic opportunities for the treatment of inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Martijn J.L. Bours (2011) conducted a review in Inflammation. Purinergic signalling system (extracellular ATP and P2 receptors) was evaluated. The purinergic signalling system, including extracellular ATP and P2 receptors, amplifies inflammation in vivo and represents a novel therapeutic target for inflammatory diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: